medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2019, Number 1

<< Back

VacciMonitor 2019; 28 (1)

Evaluation of 6-Gingerol and its modified analogues as therapeutic candidates against Schistosoma mansoni phosphofructokinase

Durojaye OA, Nwanguma BC, Joshua PE, Ogidigo JO, Cosmas S, Asomadu RO, Obeta JN

Language: English
References: 20
Page: 38-47
PDF size: 693.80 Kb.


ABSTRACT

The African most prevalent tropical disease after malaria is schistosomiasis and this disease in the developing countries is a massive socio-economic and public health burden. The disease also caused over 200,000 deaths. The development and design of new and novel antischistosomal drugs is now very important, as there are no vaccines currently and there is only one drug at the moment for the treatment of schistosomiasis. In this article, 6-gingerol was docked against the Schistosoma mansoni phosphofructokinase and the docking result was compared to those obtained from the docking of its modified analogues against the same enzyme. The chemical structure of 6-gingerol was obtained from the PubChem database while the modified analogues were designed using the ChemAxon software. The molecular docking procedure was carried out with the aid of the AutoDock Vina software while polar interactions which were eventually used in predicting the amino acid residues at the Schistosoma mansoni phosphofructokinase active site were visualized using the Pymol software. The Schistosoma mansoni phosphofructokinase 3D crystallized structure was modeled using the Swiss Model server. The molecular docking result showed that the modifications made on 6-gingerol had a positive effect on the binding energy of the compound to the enzyme active site as an appreciable increase was observed. 6-Gingerol and its modified analogues also violated none of the Lipinski’s rule with suggests that the experimental compounds are drug-like. The C2H5 analogue of 6 gingerol was selected as the ideal therapeutic agent based on the pharmacokinetics study and the exhibited binding energy.


REFERENCES

  1. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Ehrlich Sachs S, Sachs JD, Savioli L. Control of neglected tropical diseases. N. Engl. J. Med. 2007;357:1018-27.

  2. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006;6:411-25.

  3. Bueding E, Mansour JM. The relationship between inhibition of phosphofructokinase activity and the mode of action of trivalent organic antimonials on Schistosoma mansoni. British Journal of Pharmacology and Chemotherapy 1957;12:159-65.

  4. Matthaiou DK, Panos G, Adamidi ES, Falagas ME. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis. 2008;2(3):e194. doi: 10.1371/journal.pntd.0000194.

  5. Sirivichayakul C, Radomyos P, Praevanit R, Pojjaroen-Anant C, Wisetsing P, Hymenolepis nana infection in Thai children. J. Med. Assoc. Thai. 2000;83:1035-38.

  6. GenBank®: Nucleotide Sequence Database [database on the Internet]. Bethesda (MD), USA: National Institutes of Health. National Library of Medicine. National Center for Biotechnology Information. 2007. [cited 2018 Nov 7th]. Available from: https://www.ncbi.nlm.nih.gov/

  7. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673-80.

  8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235-42.

  9. Chen J, Swamidass SJ, Dou Y, Bruand J, Baldi P. ChemDB: a public database of small molecules and related chemoinformatics resources. Bioinformatics. 2005;21(22):4133-9.

  10. O´Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Chem inform 2011;3:33. doi: 10.1186/1758-2946-3-33

  11. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt D.M, Meng EC. Ferrin TE. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004;25(13):1605-12.

  12. Zhu K, Day T, Warshaviak D, Murrett C, Friesner R, Pearlman D. Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction. Proteins 2014;82(8):1646-55.

  13. Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: current status and future challenges. Proteins 2006;65(1):15-26.

  14. Kolodny R, Petrey D, Honig B. Protein structure comparison: implications for the nature of ‘fold space’, and structure and function prediction. Curr. Opin. Struct. Biol. 2006;16:393-8.

  15. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;4(1-3):3-26.

  16. Ritchie TJ, Macdonald SJ, Peace S, Pickett SD, Luscombe CN. Increasing small molecule drug developability in suboptimal chemical space. Med Chem Comm 2013;4:673-80

  17. Bogentoft C, Carlsson I, Ekenved G, Magnusson A. Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms. Eur J Clin Pharmacol 1978;14(5):351-5.

  18. Wolak DJ, Thorne RG. Diffusion of macromolecules in the brain: implications for drug delivery. Mol Pharm. 2013;10(5):1492-504.

  19. Seeliger D, de Groot LB. Ligand Docking and Binding Site Analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24(5):417-422.

  20. Schellman JA, Schellman CG. Kaj Ulrik Linderstrøm-Lang (1896–1959). Protein Sci. 1997;6(5):1092-100. doi:10.1002/pro.5560060516.




2020     |     www.medigraphic.com